Ann: Kazia releases Cantrixil top line final data, page-11

The reality is there are many drugs that show some potential that get shelved because the funds aren't there to trial them all.Cantrixil may be one of those. I get the feeling they take a royalty licensing deal if anyone shows interest in taking it on and continuing the trials. If there is no interest then it will have to sit on the shelf. At some stage, assuming a deal around Paxsalisib, Kazia will need a transformative strategy as to where it goes next. Paxsalasib is an all or nothing roll of the dice appropriate to where the company found itself a few years ago. I don't think the company can take those sort of risks in future.